Nivolumab,Ipilimumab
BMS
[]
at 3yr follow up of cm-649 the trends continue. 3yr os rates of 21% in pd-l1 cps &gt;= 5 and 17% in all randomized. #gi23 
Healthcare publisher of oncology focused articles, videos, panel discussions, and much more that run the gamut of oncology care and management.